Abstract
MicroRNAs have emerged as key players of gene regulation during development and disease states like cancer and cardiovascular diseases. Pulmonary arterial hypertension (PAH), a vascular disease characterized by pulmonary resistance and vessel occlusion, is not spared by microRNA implication. This is not surprising since PAH shares common aberrantly activated pathways with cancers that lead to proliferation and survival of pulmonary arterial smooth muscle cells, among others, within the artery wall and narrowing the lumen. Recent studies demonstrated the role of miR-204 and miR- 206 in pulmonary artery smooth muscle cell (PASMC) proliferation. Other microRNAs, such as miR-145, miR-21 and the miR17/92 cluster, have been associated with the disrupted BMPR2 pathway. During the last couple of years, the number of studies on the role of microRNA in PAH has broadened, defining it clearly as a HOT TOPIC. This current review presents an overview of the most recent knowledge as well as future possibilities. The use of microRNA therapies is still uncertain and poorly applied in the clinical setting yet. It is still critical to increase the knowledge and the translational potential of this HOT TOPIC to make it become a HOPE TOPIC.
Keywords: Biomarker, microRNA, molecular biology, pulmonary arterial hypertension, remodeling, therapeutic target.
Current Vascular Pharmacology
Title:Therapeutic Potential of microRNA Modulation in Pulmonary Arterial Hypertension
Volume: 13 Issue: 3
Author(s): Jolyane Meloche, Roxane Paulin, Steeve Provencher and Sebastien Bonnet
Affiliation:
Keywords: Biomarker, microRNA, molecular biology, pulmonary arterial hypertension, remodeling, therapeutic target.
Abstract: MicroRNAs have emerged as key players of gene regulation during development and disease states like cancer and cardiovascular diseases. Pulmonary arterial hypertension (PAH), a vascular disease characterized by pulmonary resistance and vessel occlusion, is not spared by microRNA implication. This is not surprising since PAH shares common aberrantly activated pathways with cancers that lead to proliferation and survival of pulmonary arterial smooth muscle cells, among others, within the artery wall and narrowing the lumen. Recent studies demonstrated the role of miR-204 and miR- 206 in pulmonary artery smooth muscle cell (PASMC) proliferation. Other microRNAs, such as miR-145, miR-21 and the miR17/92 cluster, have been associated with the disrupted BMPR2 pathway. During the last couple of years, the number of studies on the role of microRNA in PAH has broadened, defining it clearly as a HOT TOPIC. This current review presents an overview of the most recent knowledge as well as future possibilities. The use of microRNA therapies is still uncertain and poorly applied in the clinical setting yet. It is still critical to increase the knowledge and the translational potential of this HOT TOPIC to make it become a HOPE TOPIC.
Export Options
About this article
Cite this article as:
Meloche Jolyane, Paulin Roxane, Provencher Steeve and Bonnet Sebastien, Therapeutic Potential of microRNA Modulation in Pulmonary Arterial Hypertension, Current Vascular Pharmacology 2015; 13 (3) . https://dx.doi.org/10.2174/15701611113119990010
DOI https://dx.doi.org/10.2174/15701611113119990010 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Heme Oxygenase-1 in Vascular Smooth Muscle Cells Counteracts Cardiovascular Damage Induced by Angiotensin II
Current Neurovascular Research Editorial [Hot Topic:Translating Clinical Evidence into the Practice of Diabetes Care (Guest Editor: Richard W. Grant Contents)]
Current Diabetes Reviews Foreword [ Current Vascular Pharmacology is 10 Years Old! ]
Current Vascular Pharmacology Pulmonary Hypertension in the Critically Ill
Current Hypertension Reviews Assessment of Admission Time Cell Blood Count (CBC) Parameters in Predicting Post-primary Percutaneous Coronary Intervention TIMI Frame Count in Patients with ST-segment Elevation Myocardial Infarction
Cardiovascular & Hematological Disorders-Drug Targets Corticosteroid as an Adjunct in the Treatment of Endobronchial Tuberculosis: A Systematic Review & Meta-analysis
Current Pediatric Reviews Lycopene and Cardiovascular Diseases: An Update
Current Medicinal Chemistry Editorial (Hot Topic:Current Situation at Perioperative of Cardiovascular Disease Patients: New Addressing and Perioperative Optimization Techniques)
Current Pharmaceutical Design Update on Drug Interactions With Phosphodiesterase-5 Inhibitors Prescribed as First-Line Therapy for Patients with Erectile Dysfunction or Pulmonary Hypertension
Current Drug Metabolism Acute Renal Failure in Different Malignant Tumors
Current Medicinal Chemistry Mutual Modulation of Femarelle and Vitamin D Analog Activities in Human Derived Female Cultured Osteoblasts
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Editorial (Thematic Issue: Metabolic Syndrome in Pregnancy)
Current Pharmaceutical Biotechnology Do Adenosine Receptors Offer New Therapeutic Options for Diabetic Nephropathy?
Current Vascular Pharmacology Roles of Calcium and Tyrosine Kinases in the Pathogenesis of Type 2 Diabetes Mellitus
Current Enzyme Inhibition Beneficial Effects of Selective Vitamin D Receptor Activation by Paricalcitol in Chronic Kidney Disease
Current Drug Targets Comparative Studies on Hormonal Changes and Metabolic Syndrome in Perimenopausal and Premenopausal Igbo Women in Enugu Metropolis Nigeria: A Cross-sectional Study
Current Women`s Health Reviews Stability-indicating UPLC-PDA Method for Ambrisentan Tablets and Identification of a Main Degradation Product by UPLC-MS/MS
Current Pharmaceutical Analysis Aortic Dissection: A Review of the Pathophysiology, Management and Prospective Advances
Current Cardiology Reviews Primary Prevention of Cardiovascular Risk in Octogenarians by Risk Factors Control
Current Hypertension Reviews Vascular C-Reactive Protein in the Pathogenesis of Coronary Artery Disease:Role of Vascular Inflammation and Oxidative Stress
Cardiovascular & Hematological Disorders-Drug Targets